2634-33-5
CAS 2634-33-5
2634-33-5 (CAS 2634-33-5) is a pharmaceutical compound with 3 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 21044.087037037036 nM | 53 | - |
| - | IC50 | 27091.5 nM | 15 | - |
| - | EC50 | 8116 nM | 2 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| BENZISOTHIAZOLINONE | 1368198 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 2634-33-5 used for in pharmaceutical contexts?
2634-33-5 (CAS 2634-33-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 2634-33-5?
No adverse-event association or SIDER side-effect rows are rendered for 2634-33-5 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 2634-33-5 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Benzisothiazolinone with EU status "restricted".
What clinical phase is 2634-33-5 in?
No phase 1-4 clinical development badge is rendered for 2634-33-5 because the matched compound identifier rows do not contain a max-phase value.